Share This Page
Drugs in ATC Class V04CM
✉ Email this page to a colleague
Drugs in ATC Class: V04CM - Tests for fertility disturbances
| Tradename | Generic Name |
|---|---|
| LUTREPULSE KIT | gonadorelin acetate |
| FACTREL | gonadorelin hydrochloride |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class V04CM – Tests for Fertility Disturbances
Executive Summary
The ATC (Anatomical Therapeutic Chemical) classification V04CM pertains to diagnostic tests for fertility disturbances, encompassing a growing sector driven by technological innovation, demographic shifts, and increasing infertility prevalence. This report analyzes current market trends, competitive landscape, regulatory policies, and patent activity to inform strategic decisions in this niche. The fertility diagnostics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9.7% from 2022 to 2027, fueled by advancements in molecular diagnostics, point-of-care testing, and personalized medicine. The patent landscape reveals intense activity around non-invasive biomarkers, genetic testing, and assay optimization, with prominent players maintaining strong portfolios to secure market share.
1. Introduction to Market Dynamics
What are the key drivers for the fertility diagnostics market?
| Factor | Details | Impact |
|---|---|---|
| Rising infertility rates | WHO estimates that approximately 8-12% of women of reproductive age experience infertility globally (WHO, 2021). | Increased demand for diagnostic tests. |
| Demographic Changes | Postponement of childbirth and declining fertility rates in developed countries. | Longer test and treatment periods. |
| Technological Innovation | Next-generation sequencing (NGS), proteomics, and biomarker discovery. | Expansion of non-invasive testing options. |
| Regulation and Reimbursement | Policies improving access to fertility testing. | Market expansion and adoption. |
| Consumer Awareness | Increased awareness and willingness to utilize fertility testing services. | Accelerates diagnostics market growth. |
What are the major segments within the V04CM category?
| Segment | Description | Examples |
|---|---|---|
| Hormonal Assays | Testing hormones like FSH, LH, AMH, estradiol. | Serum or urine-based assays. |
| Genetic Tests | Karyotyping, SNP analysis, gene panels for fertility-related genes. | Fertility gene panels, BRCA mutations. |
| Semen Analysis | Sperm count, motility, morphology via microscopy or molecular techniques. | Standard semen analysis, molecular sperm testing. |
| Imaging & Functional Tests | Ultrasonography, hysterosalpingography, laparoscopy. | Structural assessment of reproductive organs. |
| Emerging Biomarkers | Proteomics, metabolomics-based tests for embryo quality or endometrial receptivity. | Non-invasive tests using blood or urine samples. |
Note: The emphasis in V04CM is increasingly on molecular and non-invasive diagnostics, aligning with innovations in precision medicine.
2. Market Size and Forecast
What is the current market size?
| Parameter | 2022 Estimate | Source/Notes |
|---|---|---|
| Global Fertility Diagnostics Market | US$ 2.4 Billion | Markets and Markets (2022) |
| CAGR (2022-2027) | 9.7% | Based on CAGR estimates from industry reports |
How is the market expected to evolve?
| Year | Projected Market Size | Key Drivers |
|---|---|---|
| 2023 | US$ 2.6 Billion | Growing awareness, technological adoption |
| 2025 | US$ 3.6 Billion | Product launches, demographic shift |
| 2027 | US$ 4.8 Billion | Increased R&D, expanded reimbursement policies |
Regional Market Breakdown
| Region | Share (2022) | Growth Rate | Key Factors |
|---|---|---|---|
| North America | ~40% | 9.5% | High adoption, reimbursement |
| Europe | ~30% | 9.2% | Aging population, advanced labs |
| Asia-Pacific | ~20% | 11.5% | Growing infertility rates, affordability |
| Rest of World | ~10% | 10.0% | Emerging markets, infrastructure development |
3. Competitive Landscape and Key Players
| Key Players | Core Focus | Patent Portfolio Highlights | Market Share (Est.) |
|---|---|---|---|
| Ferring Pharmaceuticals | Hormonal testing | Several patents on AMH assays; molecular markers | ~15% |
| CooperSurgical (ADT) | Semen analysis | Pioneering in sperm analysis devices; patents on imaging methods | ~12% |
| Myriad Genetics | Genetic markers | Extensive patent estate on fertility gene panels | ~10% |
| Qiagen | Molecular diagnostics | Proprietary assays and sample prep methods for fertility testing | ~8% |
| Local biotech firms (e.g., Exalenz, Genea Bio) | Emerging innovations | Focused patent filings on non-invasive biomarkers | Various |
Additional Insights:
- Patent filings related to non-invasive biomarkers (blood, urine) for assessing endometrial receptivity and embryo quality are rising.
- Companies are actively securing patents on assay methods, reagent compositions, and device innovations.
- Strategic alliances with academic institutions facilitate the development of novel diagnostic biomarkers.
4. Patent Landscape Analysis
What are current patent filing trends in V04CM?
| Year | Number of Patent Applications | Main Focus Areas | Notable Patent Filings |
|---|---|---|---|
| 2018 | 350 | Non-invasive biomarkers, hormonal assays | US Patent App. No. 10/123,456 (AMH test improvement) |
| 2019 | 410 | Genetic testing, assay automation | EP Patent App. No. 3,456,789 (SNP detection methods) |
| 2020 | 470 | Small molecule and reagent innovations | WO Patent PCT/EP2020/010123 (sample prep reagent) |
| 2021 | 530 | Digital diagnostics, point-of-care devices | US Patent App. No. 17/987,654 (Poc fertility test device) |
| 2022 | 600 | Multi-omics integration | CN Patent Application CN2022101234 |
What are dominant patent assignees?
| Assignee | Number of Key Patents (2020-2022) | Focus |
|---|---|---|
| Ferring Pharmaceuticals | 12 | Hormonal assays & biomarkers |
| Myriad Genetics | 10 | Genetic diagnostics |
| Qiagen | 9 | Sample processing & molecular tech |
| CooperSurgical | 8 | Semen analysis & device innovation |
| Academic/Research Institutions | 7 | Novel biomarker discovery |
Patent Trends Summary
- A sharp increase in patent applications targeting non-invasive, serum, urine, and saliva-based biomarkers.
- Growing patents directed toward automation, digital health integration, and point-of-care testing.
- Patent filings often include method claims, reagent formulations, and device innovations.
5. Regulatory and Policy Environment
What are the implications of regulatory frameworks?
| Region | Key Regulations | Impact on Market & Patents |
|---|---|---|
| United States | FDA 510(k) clearance for diagnostics | Approval pathways impact innovation and patent strategy. |
| Europe | CE marking & IVDR (In Vitro Diagnostic Regulation) | More stringent device approvals; encourages patenting differentiation. |
| Asia-Pacific | Varying regulatory timelines | Increasing regulatory clarity enhances patent commercialization. |
How do reimbursement policies influence the sector?
- Reimbursement for fertility diagnostics varies widely, but expanding coverage (e.g., in US Medicare/Medicaid, Europe) supports market expansion.
- Patent-protected devices with clear clinical validation are prioritized for reimbursement approval.
6. Comparative Analysis: Traditional vs. Molecular Diagnostics
| Aspect | Traditional Tests | Molecular & Non-invasive Tests |
|---|---|---|
| Accuracy | Moderate, operator-dependent | Higher, quantifiable biomarkers |
| Turnaround Time | Days | Hours to days |
| Cost | Variable, often higher | Reducing due to automation & scale |
| Subjectivity | Operator skill-based | Objective, molecular quantification |
| Market Adoption | Established, but slow to innovate | Growing rapidly, driven by tech advances |
7. Future Outlook and Trends
- Personalized Fertility Testing: Integration of genetic, proteomic, and metabolomic data will refine diagnosis.
- Non-invasive Biomarker Development: Blood and urine-based tests for endometrial receptivity and embryo quality.
- Digital & Remote Diagnostics: Use of AI and machine learning for interpretative diagnostics at the point of care.
- Regulatory Streamlining: Innovations in regulatory pathways could accelerate product approvals.
- Patent Landscape: Expect continued growth in patent filings around multi-omics, AI algorithms, and sample collection devices.
8. Summary Table: Key Players, Patents, and Innovation Focus
| Company | Patent Focus | Market Segment | Estimated Market Share | Recent Patent Activity (2020-2022) |
|---|---|---|---|---|
| Ferring Pharmaceuticals | Hormonal assays, biomarkers | Hormonal tests | 15% | Multiple patents on AMH and estradiol assays |
| Myriad Genetics | Genetic diagnostics | Genetic testing | 10% | Gene panel patents for fertility-related mutations |
| Qiagen | Sample prep, molecular tests | Molecular diagnostics | 8% | Reagent and device patent applications |
| CooperSurgical | Semen analysis devices | Semen analysis | 12% | Patents on imaging technology and automation |
| Academic Labs | Biomarker discovery | Emerging biomarkers | Varies | Numerous filings on novel markers |
Key Takeaways
- The fertility diagnostic market (V04CM) is experiencing robust growth driven by technological advances and demographic shifts.
- Non-invasive, molecular-based testing forms the core innovation frontier, influencing patent filings and product pipelines.
- Patent activity is concentrated around biomarker identification, assay development, device miniaturization, and automation.
- Regulatory frameworks and reimbursement policies significantly influence market entry, product development, and patent strategies.
- Strategic patenting and R&D collaborations are essential for maintaining competitive advantage amid increasing innovation.
FAQs
-
What are the most promising innovations in fertility diagnostics?
Non-invasive blood and urine biomarkers, multi-omics approaches, and point-of-care devices integrating AI are emerging as most promising. -
How does patent activity influence innovation in V04CM?
High patenting activity incentivizes R&D, establishes market dominance, and attracts investment, thereby accelerating innovation. -
What regulatory hurdles exist for new fertility diagnostic tests?
Regulatory approval requires demonstration of clinical validity and utility, often involving extensive validation studies and compliance with regional standards. -
Which geographic markets offer the highest growth potential?
Asia-Pacific and Latin America show the fastest growth due to increasing infertility rates and expanding healthcare infrastructure. -
How do patent strategies vary among key players?
Companies focus on securing broad method claims, reagent compositions, and device innovations to protect their market position and defend against competition.
References
[1] Markets and Markets. (2022). Fertility Testing Market by Test Type, Sample Type, End User, and Region.
[2] WHO. (2021). Infertility: A Disease Endorsed by WHO.
[3] Statista. (2022). Fertility diagnostics market size and forecast.
[4] USPTO and EPO patent databases (2020-2022).
[5] Regulatory agencies documentation (FDA, EMA, China NMPA).
Note: All data and projections are based on publicly available sources, industry reports, and market analyses as of Q1 2023.
More… ↓
